Publications by authors named "Paul Bore"
Introduction: Immune checkpoint inhibitors (ICI) are the standard of care for non-small-cell lung cancer (NSCLC) regardless of program death ligand-1 (PDL1) expression. However, a majority of patients presented early progression, underlining the need for better patient selection. The aim of this study was to determine effective clinical and biological biomarkers of real-world progression-free survival (rwPFS) in addition to PDL1.
View Article and Find Full Text PDFAbscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study.
Cancers (Basel)
August 2022
Article Synopsis
- The study aimed to assess the occurrence of the abscopal response (AR) in metastatic melanoma patients undergoing palliative radiotherapy, focusing on those receiving specific conditions of systemic treatments.
- Out of 118 patients analyzed, 15 (12.7%) exhibited an AR, showing significantly improved overall survival and progression-free survival compared to those without an AR.
- The findings suggest that AR is a rare but important indicator of better prognosis and may be enhanced by concurrent treatments like immunotherapy and infections during radiotherapy.
Introduction: Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) with paclitaxel-bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lung cancer (NSCLC). With the increase of immunotherapy treatment in first-line settings, the optimal treatment after first-line failure must be redefined.
Methods: This multicentric retrospective study identified all advanced NSCLC patients treated with PB as second-line therapy and beyond.
Objectives: Brigatinib is a second-generation ALK inhibitor which demonstrated activity over crizotinib-resistance, especially on brain metastasis by increased blood-brain penetration. However, its activity on lepto-meningeal disease is unknown and scarcely reported.
Materials And Methods: We hereby report the case of lepto-meningeal disease in crizotinib- and ceretinib- treated patient who was successfully treated by brigatinib.
False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma-A Caution for Reporting Physicians.
Front Med (Lausanne)
October 2018
Article Synopsis
- Schwannoma can cause false-positive results in 18F-FDG PET/CT scans, which may lead to incorrect cancer staging and affect patient treatment decisions.
- A case study discusses a patient who had an 18F-FDG PET/CT scan for ovarian adenocarcinoma, which showed a concerning hypermetabolic mass in the mediastinum.
- After biopsy, it was determined that the mass was a Schwannoma, clearing the patient for surgery on her ovarian adenocarcinoma by ruling out malignancy from the mass.